Arphra
live
S&P 5007,500.58+1.08%
NASDAQ30,406.19+2.48%
DOW51,564.7+0.14%
VIX16.78+2.32%
US10Y4.45-0.27%
EUR/USD1.1506-0.93%
GOLD4,300.5-1.26%
WTI75.22-0.90%
BTC64,442.01-1.87%
S&P 5007,500.58+1.08%
NASDAQ30,406.19+2.48%
DOW51,564.7+0.14%
VIX16.78+2.32%
US10Y4.45-0.27%
EUR/USD1.1506-0.93%
GOLD4,300.5-1.26%
WTI75.22-0.90%
BTC64,442.01-1.87%

SHTDF

Sinopharm Group Co. Ltd.
HealthcareMedical - DistributionCNUSDPeers →via fmp_bulkCountry macro →
$2.29
LiveJun 22, 2026
AI Brief
Market cap
$7.15B
52w range
2.11 – 2.70
P / E
EPS
Volume
800
Revenue · FY

Explain this page

Arphra AI
Business description
· company · SEC profile

Sinopharm Group Co. Ltd.

Sinopharm Group Co. Ltd., along with its affiliates, plays a significant role in the People's Republic of China's healthcare sector, primarily engaging in the wholesale and retail trade of pharmaceuticals, medical equipment, and health-related products. The company organizes its extensive operations across four distinct divisions. Its Pharmaceutical Distribution unit supplies a wide array of medicinal products to various clients, including hospitals, other distributors, retail pharmacies, and clinics. This segment also provides comprehensive distribution, logistics, and additional value-added services for both domestic and international pharmaceutical and healthcare product manufacturers and suppliers. The Medical Devices segment is dedicated to the distribution of medical equipment. Through its Retail Pharmacy division, the company oversees and franchises a substantial network of drugstores, which totaled 10,259 locations as of December 31, 2021. The Other Business segment is involved in the manufacturing and sale of pharmaceuticals, chemical reagents, and laboratory supplies. Beyond these core areas, the company's activities extend to property leasing and management; the trade of specialized medical instruments, traditional Chinese herbal medicines, antibiotics, and biological products; information technology development; a variety of consulting services (medicine, health, business, market information); investment management; import and export; and convention and exhibition services. Additionally, it manages medical project investments, consulting, and technology training initiatives. Sinopharm Group Co. Ltd. has formed a strategic partnership with I-Mab to enhance its commercial reach and market transformation efforts. The company was established in 2003, with its headquarters located in Shanghai, China, and operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.

Founded
IPO
Apr 21, 2011
Employees
108,217
HQ
Shanghai
CEO
Wanyong Lian
CFO
Exchange
OTC
Fiscal year
Identifiers
· company_identifiers
CIK
CUSIP
ISINCNE100000FN7
FIGI
LEI
Cross-listings
· companies · ISIN
  • 1099.HKPrimaryHong Kong Stock ExchangecnHKD$6.52B
  • SHTDFOTCUSD$7.15B
  • SHTDYOTCUSD$6.61B
The global universe keeps only the primary listing; the other venues for this security are shown here.